Rare Disease Day reminds us: “rare” isn’t all that rare. Around 400 million people worldwide—more than cancer and AIDS combined—live with one of over 10,000 rare diseases, 70% of which are genetic and often start in childhood [1,2]. Although definitions vary internationally, Canada generally considers a condition rare when it affects fewer than 1 in …
Continue reading “Bringing Awareness to Rare Disease Day 2026”
AI has moved far beyond the hype in healthcare and into diagnostics: AI systems are now reading scans, drafting notes, assessing risk, and even proposing treatment options. But as the pace accelerates, so do clinicians’ concerns about skill erosion, liability, and whether AI can truly deliver on what it promises. This article opens a four-part …
Continue reading “AI In Healthcare (1): The Machine Will See You Now — AI in Diagnostics”
One of the latest health crazes to slip in alongside “peptides” (see our previous series), is the idea that powerful medicines can be repurposed as lifestyle tweaks by “microdosing”: a tiny dose of a diabetes drug to “optimize” metabolism, a fraction of a psychedelic to sharpen focus, or a whisper of a stimulant to fuel …
Continue reading “Beyond the Hype: Why Microdosing Falls Short of Science”
The first article of this series argued that the peptide boom is not just a fringe fad but a parallel ecosystem, built by people who feel conventional medicine is too slow, too narrow, or too inaccessible for the goals they care about. In our second article, we asked how far bodily autonomy should extend when …
Continue reading “The Peptide Paradox (3): When the System Has No Middle Ground”
In the first article of this series we explored how collapsing trust in traditional evidence-based systems is fueling the recent boom in the unregulated peptide market. But this gray‑market peptide trend reveals more than a pushback against entrenched regulatory mechanisms. It exposes a deeper ethical divide in modern medicine: a clash between medical paternalism, where doctors …